Shoreline Biosciences to Present at 2024 Stifel Healthcare Conference
San Diego, November 14, 2024 – Shoreline Biosciences, Inc., a biopharmaceutical company developing disease modifying iNK cell therapies for autoimmune…
Shoreline Biosciences to Participate at the 2023 Wedbush Pacgrow Healthcare Conference
SAN DIEGO, Aug. 3, 2023 /PRNewswire/ — Shoreline Biosciences, Inc. (Shoreline), a biopharmaceutical company developing effective and differentiated cellular immunotherapies based on induced pluripotent…
Shoreline Biosciences Appoints Vanessa L. Jacoby as Chief Financial Officer
May 3, 2021
No Comments
Shoreline Biosciences, Inc. (Shoreline), a biotechnology company developing intelligently designed allogeneic off-the-shelf, standardized and targeted natural killer (NK) and Macrophage cellular immunotherapies derived from induced
Shoreline Biosciences Appoints Co-Founder William Sandborn, M.D. as Chief Medical Officer
April 26, 2021
No Comments
Shoreline Biosciences, Inc. (Shoreline),a biotechnology company developing intelligently designed allogeneic off-the-shelf, standardized and targetedcellular immunotherapies derived from induced pluripotent stem cells (iPSC) for cancer and
Shoreline Biosciences Announces $43m Financing to Advance Pipeline of Allogeneic Natural Killer and Macrophage Cellular Immunotherapies Derived from Pluripotent Stem Cells
April 7, 2021
No Comments
Shoreline Biosciences, Inc. (Shoreline),a biotechnology company developing intelligently designed allogeneic off-the-shelf, standardized and targeted natural killer (NK) and Macrophage cellular immunotherapies derived from induced pluripotent